Is ImClone Out of the Woods?

Is ImClone Out of the Woods?
If the FDA approves its Erbitux anticancer treatment, as S&P expects, the biotech’s volatile stock should be set for solid growth


Comments are closed.

Get email updates

Get new actionable insights and updates from BiotechBlog

Do NOT follow this link or you will be banned from the site!